ANTXR2

Anthrax toxin receptor 2 · P58335 · ANTXR2 on Sugi Atlas →

3,052 patent compounds predicted against ANTXR2, 1,955 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tannic Acid (SCHEMBL409616)	0.56	4/20
Tannic Acid (SCHEMBL409692)	0.56	4/20
Tannic Acid (SCHEMBL743760)	0.56	4/20
SCHEMBL5663820	0.56	4/20
SCHEMBL5664497	0.53	4/20
SCHEMBL5665043	0.53	4/20
SCHEMBL5663969	0.52	4/20
SCHEMBL5663975	0.52	4/20
SCHEMBL5664565	0.52	4/20
SCHEMBL5664781	0.51	4/20
SCHEMBL2227165	1.00	3/20
SCHEMBL2227368	1.00	3/20
SCHEMBL2227385	0.65	3/20
SCHEMBL2226788	0.63	3/20
SCHEMBL2226958	0.63	3/20
SCHEMBL5664244	0.63	3/20
Pentagalloyl Glucose (SCHEMBL640108)	0.62	3/20
Pentagalloyl Glucose (SCHEMBL675693)	0.62	3/20
Pentagalloyl Glucose (SCHEMBL2227915)	0.62	3/20
Pentagalloyl Glucose (SCHEMBL2787135)	0.62	3/20

Clinical trials — most relevant to ANTXR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses	PHASE4	COMPLETED
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule	PHASE4	COMPLETED
Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury	PHASE3	COMPLETED
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban	PHASE2/PHASE3	COMPLETED
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection	PHASE1/PHASE2	COMPLETED
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas	PHASE2	COMPLETED
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma	PHASE2	RECRUITING
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia	PHASE2	COMPLETED
Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure	PHASE1/PHASE2	COMPLETED
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer	PHASE2	COMPLETED
Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma	PHASE1/PHASE2	RECRUITING
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer	PHASE2	COMPLETED
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae	PHASE1	COMPLETED
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS	PHASE1	UNKNOWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of APX005M in Pediatric Central Nervous System Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Pathogenic Mechanisms in C Diff Infection and Colitis	nan	COMPLETED
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial	nan	UNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia	nan	COMPLETED
Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A	nan	COMPLETED
Genetic Variation and Immune Responses After Injury	nan	UNKNOWN
Identifying New Therapeutic Targets for Lupus Treatment	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ANTXR2 binder may also engage these)

Protein	Name	Similarity
Q6DFX2	—	1.000	Q6DFX2 →
P18563	—	0.976	P18563 →
TMX1	Thioredoxin-related transmembrane protein 1	0.975	landscape →
Q9H6X2	—	0.974	Q9H6X2 →
A2A863	—	0.974	A2A863 →
Q8VBT0	—	0.973	Q8VBT0 →
O70367	—	0.971	O70367 →
Q5RAP2	—	0.971	Q5RAP2 →
Q9WTS6	—	0.970	Q9WTS6 →
Q6AYF4	—	0.969	Q6AYF4 →
Q62470	—	0.969	Q62470 →
Q1RPR6	—	0.968	Q1RPR6 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.968	landscape →
Q9UKX5	—	0.968	Q9UKX5 →
Q6Q0N0	—	0.968	Q6Q0N0 →
Q8R553	—	0.968	Q8R553 →
O94985	—	0.968	O94985 →
Q5R9Q9	—	0.967	Q5R9Q9 →
Q86UX2	—	0.967	Q86UX2 →
ITGAL	Integrin alpha-L	0.967	landscape →
F1ND48	—	0.967	F1ND48 →
A7E2Z9	—	0.967	A7E2Z9 →
P12387	—	0.967	P12387 →
ITGB4	Integrin beta-4	0.967	landscape →
Q9H8M5	—	0.966	Q9H8M5 →
O88824	—	0.966	O88824 →
Q9ER65	—	0.966	Q9ER65 →
B0S5N4	—	0.966	B0S5N4 →
P97280	—	0.966	P97280 →
Q9GLY5	—	0.966	Q9GLY5 →